Incidence rate of fluoroquinolone resistant gram-negative rod bacteremia among allogeneic hematopoietic cell transplant patients during an era of levofloxacin prophylaxis
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INTRODUCTION
Bacterial bloodborne infections are a common cause of morbidity and mortality among allogeneic hematopoietic cell transplant (HCT) patients, occurring in up to 55% of this population. 1 Gram-negative rod (GNR) bacteremia affects between 5% and 11% of patients, and is associated with higher casefatality than bacteremia caused by gram-positive organisms. [2] [3] [4] The majority of cancer/transplant centers worldwide utilize antibiotic prophylaxis during neutropenia to prevent GNR bacteremia and associated mortality in these highly immunocompromised patients.
International guidelines currently recommend the use of broad spectrum fluoroquinolones (FQ) for neutropenia prophylaxis in cancer and HCT recipients whose absolute neutrophil count is anticipated to decrease to ≤ 500/µL for at least seven days, [5] [6] [7] as they have been shown to reduce the incidence of GNR bacteremia in neutropenic patients and to decrease mortality in multiple randomized placebocontrolled trials. [8] [9] [10] Levofloxacin is the most frequently used agent due to its excellent bioavailability, oral formulation, and the convenience of once daily dosing. 11 While FQ prophylaxis has given more flexibility to outpatient cancer care, the most recent guidelines also warn that resistance should be closely monitored due to increasing FQ resistance worldwide. Recent studies of HCT recipients have suggested that the incidence of GNR bacteremia is increasing in this population, 1, 12 including one study at our center. 13 Some have speculated that increasing FQ use and development of associated antimicrobial resistance may play a major role in this change. 12 However, available data that have examined the emergence of FQ-resistant GNR bacteremia among high-risk patient populations who receive FQ prophylaxis have been inconsistent. 1, 12, 14 Additionally, it is unknown if HCT recipients who develop FQresistant GNR bacteremia have an associated increased mortality when compared to patients who develop FQ-sensitive GNR bacteremia, as most studies have had insufficient power to address this important question.
Levofloxacin prophylaxis became standard practice for neutropenic prophylaxis for adult HCT recipients at the Seattle Cancer Care Alliance (SCCA)/Fred Hutchinson Cancer Research Center (FHCRC) in August 2002. In order to better understand trends in GNR bacteremia and FQ-resistant GNR bacteremia during this era of levofloxacin prophylaxis, we conducted a retrospective cohort study of allogeneic HCT recipients who were transplanted between January 2003 and December 2012. Our primary goal was to determine annual trends in the incidence of GNR bacteremia and FQ-resistant GNR bacteremia during the first 100 days post-transplant in this cohort. In addition, we compared 30-day mortality between HCT recipients with FQ-resistant GNR bacteremia and those with FQ-sensitive GNR bacteremia.
METHODS

Study Population
All adults (≥18 years) who underwent an allogeneic HCT between 1/1/2003 and 12/31/2012 at the SCCA/FHCRC were eligible for inclusion in this study. For those patients who had multiple allogeneic transplants during the study period of interest, each transplant was considered separately. The study was approved by the FHCRC Institutional Review Board, and all participants provided written informed consent according to the principles of the Declaration of Helsinki.
Microbiologic assessment and antibacterial prophylaxis
Center based standard practice guidelines recommend that two sets of anaerobic and aerobic blood cultures are drawn when a patient presents with a fever, and daily blood cultures are recommended until an alternative source of the fever is identified or the patient defervesces. Although standard recommendations exist, blood cultures are ultimately drawn at the discretion of the healthcare teams.
Similarly, the frequency of repeat blood cultures during this time period was determined by the primary healthcare provider, with the exception of surveillance blood cultures that are routinely drawn per protocol from patients who are treated with high dose glucocorticoids (> 0.5mg/kg). Since steroids are known to blunt febrile responses, 15 these surveillance cultures are drawn bi-weekly while inpatient, weekly on outpatient discharge, and are discontinued following tapering of glucocorticoids to <0.5mg/kg. The vast majority of blood cultures in SCCA patients are drawn through central venous catheters or ports during post-HCT care; peripheral blood cultures are drawn at physician discretion.
HCT recipients at the SCCA/FHCRC receive 750 mg levofloxacin daily for prophylaxis at the start of neutropenia and continue until neutrophil recovery (ANC >500/µL); levofloxacin is re-started for patients whose ANC drops below 500/µL at other points during their post-transplant care. As per center- simplex/varicella zoster virus prophylaxis. All patients undergo CMV preemptive surveillance/therapy as has been previously described. 13 
Data collection
These data were extracted from prospectively collected databases maintained by the FHCRC that include demographic, laboratory, and clinical data from all patients undergoing HCT. Additional microbiologic data were collected through electronic medical record review. Allogeneic HCT recipients remain at the center for a minimum of 100 days post-transplant, assuring complete post-transplant data capture during this time period.
Definitions
GNR bacteremia was defined as the isolation of any GNR from a blood culture specimen. To reduce the likelihood of misclassifying repeat blood cultures from a primary bacteremia event as separate bacteremia events, positive cultures for the same organism collected ≤14 days from a prior positive culture were considered part of the primary event. Similarly, early post-transplant GNR events were excluded if the same organism was isolated in a pre-transplant culture in a similar 14-day window. Positive cultures for different bacterial genus/species, even if they occurred within 14 days from a documented GNR event,
were considered unique events. Cultures that isolated multiple GNR organisms on the same day were considered one GNR event and classified as polymicrobial bacteremia.
FQ-resistant GNR bacteremia was defined as the isolation of a GNR organism that was classified as either intermediate or resistant to levofloxacin or ciprofloxacin. Sensitivities to levofloxacin and ciprofloxacin were used because 1) they had routine sensitivities performed against them in our population and 2) FQ resistance is known to exhibit a "class effect", where a decrease in susceptibility to one drug likely means a similar decrease in all FQs. 16 FQ sensitivities were determined by the University of Washington Medical Center Microbiology Laboratory using Kirby-Bauer or E-tests, and interpreted using current Clinical and Laboratory Standards Institute (CLSI) guidelines at the time of GNR isolation. 
Statistical analysis
For the primary evaluation of GNR incidence, we considered only the first GNR bacteremia event per
transplant. The incidence rates of GNR bacteremia and FQ-resistant GNR bacteremia during 30 and 100 days post-transplant were calculated for each calendar year interval. Each patient contributed patientdays at risk from the day of transplant until death, re-transplant, 30 or 100 days post-transplant, or first GNR bacteremia event, whichever occurred first. Changes in incidence rates over time were assessed using a Poisson regression model, with time in one-year intervals as the main independent variable, and count of occurrence of a GNR bacteremia event post-transplant as the dependent variable. Patient-days at risk were included as an offset term to account for the varying follow-up time among transplants.
Incidence rate ratios (IRR) were used as the measure of change. Clustered robust standard errors were used to account for the correlation between transplants of patients who underwent multiple transplants during our time period of interest.
Next, we conducted analyses considering all GNR bacteremia events for each transplant. In these analyses, each patient contributed patient-days at risk from the day of transplant until death, 30 or 100 days post-transplant, or re-transplant, whichever occurred first. The dependent variable in this analysis was the total count of GNR bacteremia events post-transplant. Changes in incidence rates over time were assessed using similar methods to those described above.
For all analyses, estimated changes in incidence rates were first calculated in unadjusted models to assess the average overall change regardless of the mechanism. We then constructed models that included known risk factors for GNR bacteremia. These covariates were selected a priori and included:
age at transplant, severity of underlying illness (low, medium, and high), conditioning regimen score (nonmyeloablative, non-total-body irradiation, total-body irradiation with ≤12 Gray (Gy), total-body irradiation with >12 Gy), presence of severe gut graft versus host disease (GVHD, ≥grade 2), and graft type (bone marrow, peripheral blood, or cord blood). Severity of underlying illnesses categories were defined by outcomes previously observed at our center, while conditioning regimens were first divided into nonmyeloablative and myeloablative, with myeloablative further subdivided by dose of total-bodyirradiation used. 18 Following the examination of the main results, we elected to conduct post-hoc exploratory analyses to quantify the trends of GNR bacteremia and FQ-resistant GNR bacteremia incidence rates between 2003 and 2009 and separately for 2009 to 2012. These analyses were conducted for first events, all events, day 0-30, and day 0-100. Changes in incidence rates over time were assessed using the same methods described above.
Lastly, the 30-day all-cause cumulative mortality was compared between patients who developed FQ-resistant GNR bacteremia and those who developed FQ-sensitive GNR bacteremia using Kaplan
Meier estimates and the log-rank test. Cox proportional hazards regression models were used to compare the risk of death during 30-days following the first positive GNR blood culture. These analyses were performed both without adjustment for any covariates and with adjustment for underlying disease severity, conditioning regimen score (both defined above), and age at transplant. All analyses were performed using Stata version 13 (StataCorp, College Station, TX).
RESULTS
Of the 2306 transplants included in this cohort, 283 (12.3%) experienced at least one GNR bacteremia event during the first 100 days post-transplant. In the first event analysis of patients with available resistance data (n=256), there were 84/256 (33%) FQ-resistant events, and 172/256 (67%) FQ-sensitive events; 27 GNR events had no resistance data available. The selected demographic and clinical characteristics of patients who experienced a GNR bacteremia event and those that did not were very similar, with the exception that patients who experienced GNR bacteremia were more likely to have severe gut GVHD (Table 1) .
Time trends in incidence rate of all GNR bacteremia
When including only the first GNR bacteremia event per transplant, the overall incidence rate of GNR bacteremia was 1.38 events per 1000 patient-days (PD) (95% CI that occurred between days 0 and 30 post-transplant, all trends over time were in the same direction as described above, but none were statistically significant ( Table 2) . Adjusting for known risk factors for bacteremia did not meaningfully change the associations observed in unadjusted analyses (Table 2) .
Results from the multiple events analyses demonstrated similar results, with minimal increases in the incidence rates of GNR bacteremia compared to the first event analysis (Table 2 and Figure 1b) .
Time trends in incidence rate of FQ-resistant GNR bacteremia
The incidence rate of FQ-resistant GNR bacteremia generally displayed similar patterns as the incidence rate of all GNR bacteremia. In the first event analysis, the overall incidence rate of FQ-resistant GNR bacteremia was 0.41 events per 1000 PD (95% CI 0.33, 0.51). The incidence rates varied over time, that occurred between days 0 and 30 post-transplant, all trends over time were in the same direction as described above, but none were statistically significant ( Table 2) . Adjusting for known risk factors for bacteremia did not meaningfully change the associations observed in unadjusted analyses (Table 2) .
Results from the multiple events analysis again found similar results, including minimal overall increases in the incidence rates of FQ-resistant GNR bacteremia compared to the first event analysis.
Survival analysis by FQ resistance
Patients who had an initial FQ-resistant GNR bacteremia event had a significantly higher 30-day postevent cumulative mortality than patients who experienced a FQ-sensitive event (20.7% vs. 9.4%, p=0.0089) (Figure 2 ). In an unadjusted survival analysis, patients with FQ-resistant GNR bacteremia had an increased risk of death through 30-days post GNR isolation than patients with FQ-sensitive bacteremia (HR 2.43, 95% CI: 1.23, 4.80). This association persisted after adjustment for severity of underlying illness, conditioning regimen score, and age at transplant (HR 2.31, 95% CI: 1.16, 4.62).
DISCUSSION
In this large single center retrospective cohort study, we examined trends in the incidence of GNR bacteremia and FQ-resistant GNR bacteremia among adult allogeneic HCT recipients over a decade during which levofloxacin was used for neutropenic prophylaxis. We found that, on average, there was no bacteremia. Importantly, these data also demonstrate that patients who developed bacteremia from FQresistant GNRs had higher 30-day mortality than those who developed bacteremia from FQ-sensitive
GNRs.
Other centers have described rising rates of GNR infections in HCT patients, but few studies have either studied trends in GNR bacteremia over time, or assessed such data after a major change in neutropenic antibiotic prophylaxis. The findings of studies that sought to quantify this association have been inconsistent, with at least one center reporting significantly increasing rates of GNR bacteremia during use of levofloxacin prophylaxis, 1 and another reporting no significant change. 12 Available data on the issue of FQ-resistance in patient populations receiving FQ prophylaxis also varies between centers.
Some have described non-significant increases in the proportion of GNR isolates that are FQ-resistant during the modern era of FQ prophylaxis, 3, 19 while others, including a previous study at our center, reported no evidence of changes in rates of FQ-resistant GNR bacteremia after initiation of levofloxacin prophylaxis. 11, 14 In contrast, other centers have described significantly increasing rates of FQ-resistant GNR during FQ prophylaxis, 12, 20 including one that only measured FQ-resistant Escherichia coli. 20 Our data are most consistent with studies that identified no significant overall increase in GNR bacteremia or FQ-resistant GNR bacteremia over time. To our knowledge, none of these studies have addressed survival differences between HCT patients who developed FQ-resistant GNR bacteremia and those who developed FQ-sensitive bacteremia, however, FQ resistance has been identified as an independent risk factor for death after infection in other populations.
12
The observed patterns of incidence rates in this study were somewhat unexpected. The most recent data from our center indicated that rates of GNR bacteremia had been increasing. 13 We hypothesized that this increase might be associated with our widespread use of levofloxacin prophylaxis, It is also important to note that standard practice changed in 2010 to discontinue collection of an extra set of blood cultures that were held for yeast and fungi. With improvements in microbiologic techniques, such methods provided no additional benefit in isolating fungal pathogens in these patients. It is possible that these extra cultures cultivated bacterial growth, and their discontinuation could have contributed to the decrease in isolation of GNR organisms. Additionally, UW Microbiology changed their blood culture system in 2010, potentially resulting in differential isolation of organisms. To address these issues, we examined the number of blood cultures ordered between 2003 and 2012, and these data demonstrated a similar time trend as the incidence rates of GNR bacteremia, suggesting that these laboratory changes did not contribute significantly to our results (data not shown). We hypothesize that many of the aforementioned factors influenced the observed recent decline in rates of GNR bacteremia, however, this study was not designed to directly attribute changes in incidence to any of these infection control interventions or laboratory variations.
Perhaps most importantly, we did not observe an increase in FQ-resistant GNR bacteremia with widespread use of levofloxacin as neutropenic prophylaxis in this population. One reason for this might be shorter periods of neutropenia and subsequent exposure intervals to levofloxacin in this population driven by a gradual increase in the number of nonmyeloablative transplants at our center over time. Another explanation is that although there is no significant change in resistance patterns overall, there could be changing resistance patterns in specific species of GNR organisms, as some have shown that the impact of FQ use on resistance may vary by organism. 26 FQs are unique in that they are synthetic antibiotics, and it was thought that they might therefore be more insulated from resistance issues. Unfortunately, overuse in medicine and in agriculture has led to reports of increasing rates of FQ resistance worldwide. 27 Lack of a significant increase in FQ-resistance observed in this study suggests that levofloxacin may continue to be a viable neutropenic prophylaxis agent in this population.
Lastly, these data show that patients with FQ-resistant GNR bacteremia had an almost 2.5 fold increased risk of death within 30-days post-infection compared to patients with FQ-sensitive GNR bacteremia. This association persisted even after adjusting for underlying disease severity, type of conditioning regimen, and age at transplant, suggesting that FQ resistance may be an independent risk factor for death in patients with GNR bacteremia. One mechanism that may explain such differences is that patients with resistant infections experience a delay in receiving adequate antimicrobial therapy, resulting in poorer outcomes. 28 Further research is needed to elucidate risk factors for the development of resistant infections, to allow for prompt identification and treatment of these patients. Overall, these data highlight the serious nature of antimicrobial resistance and the importance of continued vigilance and monitoring of FQ resistance trends in HCT recipients and other high-risk populations.
The retrospective and observational nature of this study imposes limits on the interpretation of our data. There are likely variables that have changed over time and that influence GNR bacteremia rates or FQ resistance for which we could not adjust. Additionally, there were organisms that lacked FQ sensitivity data and could not be included in the FQ resistance analysis, and it is possible that changes in the incidence of these unclassifiable organisms over time may have had a minimal effect on our results.
Finally, these data only reflect the experience of a single transplant center and may not be generalizable to other institutions. Regional variances in transplant conditioning, antimicrobial therapy, and prevalence of FQ-resistance could impact GNR bacteremia trends at other centers. However, strengths of this study include the large sample size and the valuable long-term longitudinal data, which inform evidence based decisions about use of FQ prophylaxis at our center.
In summary, these data demonstrate that rates of FQ-resistant GNR bacteremia have not significantly increased during an era of levofloxacin prophylaxis in adult allogeneic HCT recipients at our large comprehensive cancer. Recent decreases in incidence rates of GNR bacteremia were potentially a result of a combination of center-wide changes, including several important infection control interventions.
Although there is no evidence that levofloxacin prophylaxis is associated with an increase in FQ-resistant infections in HCT recipients at our center, the increased mortality associated with FQ-resistant GNR bacteremia re-enforces the importance of monitoring emerging FQ resistance in this high-risk population. Kaplan-Meier survival estimates
